Snowball logo
logo
ATBP_logo

Antibe Therapeutics Inc

ATBPF • OTCQX Не торгуется
-- $0,00 $  (0%)
Оценка
EPS
-0,25
Бета
0,584
Другое
Размер лота
1 шт.
О компании
Тикер
ATBPF
ISIN
Страна
Канада
Сектор (GICS)
Здравоохранение
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada. As of March 17, 2025, Antibe Therapeutics Inc. operates as a subsidiary of Taro Pharmaceuticals Inc.

Часто задаваемые вопросы

В каком секторе работает Antibe Therapeutics Inc (ATBPF)?

Antibe Therapeutics Inc относится к сектору Здравоохранение.

Выплачивает ли Antibe Therapeutics Inc (ATBPF) дивиденды?

Нет, Antibe Therapeutics Inc не выплачивает дивиденды.

Какой бета-коэффициент (волатильность) у Antibe Therapeutics Inc (ATBPF)?

У компании Antibe Therapeutics Inc бета 0.584, что указывает на более низкую волатильность по сравнению с рынком в целом.